Track record · closed signal

Novo Nordisk A/S (NVO) — closed signal from December 24, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on March 24, 2026.

Predicted vs. what happened

NVO price · publication thesis → realized outcomesplit-adjusted
$52.81 Published $59.15 Target $36.89 Window close $64.16 Peak
$50.50 – $54.00Entry zone — fair-value band
$52.81Published — price the day we called it
$59.15Target — the price the thesis aimed for
$64.16Peak — highest point inside the window, not a realized return
$36.89Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 16 days.

Peak price
$64.16
peak on January 23, 2026 — not a realized return
Peak gain
+21.5%
peak, from the publication price
Window close
$36.89
end-of-window price, context only
Days to target
16
Window
December 24, 2025 – March 24, 2026

The thesis — published December 24, 2025

Predicted growth
+12%
over the measurement window
Target price
$59.15
the price the thesis aimed for
Entry zone
$50.50 – $54.00
the fair-value band we waited for
Price at publication
$52.81
published December 24, 2025
Confidence
68%
how strongly the data lined up
Timeframe
Short-term (0–3 months)

Novo Nordisk just got approval for a daily Wegovy pill and is launching a U.S. direct-pay option priced at $149/month starter. That creates a near-term boost in demand, and talk of wider coverage in 2026 could make it bigger. After a strong price jump, the plan is to buy only on pullbacks for a short (0-3 month) trade because the stock may be expensive now.

Primary drivers

  • Approval of a pill makes obesity treatment easier and reaches more patients
  • Starting direct-pay sales soon should drive immediate purchases
  • Government talk about coverage could increase access and demand
  • Leading brand lets the company keep prices and customer trust

How it played out

NVO: target reached in 16 days

Lyra published NVO at $52.81 on 2025-12-24 with a short-term view for 12% growth. The thesis pointed to approval of a daily Wegovy pill, a U.S. direct-pay starter option at $149/month, possible wider coverage in 2026, and Novo Nordisk's leading brand position. It also said the trade was meant for pullbacks after a strong jump.

Inside the window, the stock reached the $59.15 target in 16 days. It peaked at $64.16 on 2026-01-23, a 21.5% gain. By 2026-03-24, it ended at $36.89. The published target was reached, so the thesis played out on its measured goal, even though the stock later fell hard before the window closed.

What happened during the window

On 2026-02-04, Novo Nordisk reported 2026 guidance that pointed to lower revenue, while articles also noted the Wegovy pill had launched in the U.S. earlier that month. On 2026-02-24, Novo Nordisk announced lower list prices for Ozempic, Wegovy, and Rybelsus starting in 2027.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Share this receipt

A scored call, published before the outcome was known. Paste the link anywhere — it unfurls as the card above.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All NVO signals